Sign In
Last checked at 
28 Oct 2019 15:00
Bioventix Plc - Director/PDMR ShareholdingBioventix Plc - Director/PDMR Shareholding
PR Newswire
London, October 28
Bioventix plc(“Bioventix” or the “Company”)
Director/PDMR Shareholding
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, was notified on 25 October 2019 of the following transaction in its ordinary shares of 5 pence each (“Ordinary Shares”):
| Director | Position | Ordinary Shares sold | Sale price per Ordinary Share | Ordinary Shares held subsequently | Percentage of issued share capital held subsequently |
| Ian Nicholson and Persons Closely Associated | Non-Executive Chairman | 2,500 | 3,158.67p | 15,500 | 0.3% |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Names | Ian Nicholson (Non-Executive Chairman) | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | See 1(a) above | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Bioventix plc | ||||
| b) | LEI | 213800225MHX7LZQY108 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument | Ordinary shares of 5 pence (“Ordinary Shares”) | ||||
| Identification code | GB00B4QVDF07 | |||||
| b) | Nature of the transaction | Sale of Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information: · Aggregated volume · Price | See 4(c) | ||||
| e) | Date of the transaction | 25 October 2019 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
For further information please contact:
| Bioventix plc Peter Harrison | Chief Executive Officer | Tel: 01252 728 001 |
| finnCap Ltd Geoff Nash/Simon Hicks Alice Lane | Corporate Finance ECM | Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
Follow the stocks
